SciFluor Life Sciences, LLC Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure
6/25/2013 11:16:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--SciFluor Life Sciences, a drug discovery and development company leveraging the transformational power of fluorine to enrich pipelines with innovative new therapeutics, today presented new preclinical data for SF0034, a novel potassium channel opener for the treatment of partial-onset seizure. Results show that SF0034 demonstrated a five-fold increase in potency, improved selectivity and a favorable pharmacological profile in a series of in vitro and in vivo preclinical models compared to ezogabine, a therapy currently approved in the U.S. and other global markets for the treatment of partial-onset seizure. These findings were presented by Scott Edwards, Ph.D., vice president, SciFluor, during a poster session held today at the 30th International Epilepsy Congress.
Help employers find you! Check out all the jobs and post your resume.
comments powered by